Skip to main content
. Author manuscript; available in PMC: 2013 May 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2012 May 1;60(1):e15–e18. doi: 10.1097/QAI.0b013e31824d30bd

Table. Determinants of antibody response to HAV immunization.

Label Value Unadjusted Adjusted
HAV Antibody Response# OR (95% CI)& p-value OR (95% CI)& p-value
No (N=225) Yes (N=148)
Hormonal Contraception no HC 205(91.1) 132(89.2) 0.66 -ref-
Depo or OCP 20(8.9) 16(10.8) -ref- 1.3 (0.6, 2.6) 0.54
Age Mean±SD 41.6± 7.6 41.7± 8.2 1.24 (0.6, 2.5) 0.95
Race/Ethnicity* White 24 (11)$ 29 (20) 0.004
Hispanic 83 (37) 31 (21)
African-American 112 (50) 84 (57) -ref-
Other 6 (3) 4 (3) 0.3 (0.2, 0.6)
Exposure Intravenous drug use 45 (20) 35 (24) 0.6 (0.3, 1.1) 0.30
Heterosexual 106 (47) 70 (48) 0.6 (0.1, 2.2)
Transfusion 8 (4) 1 (1)
No identified risk 65 (29) 41 (28) -ref-
Group Prevalent case 98 (44) 61 (41) 0.8 (0.5, 1.5) 0.67
Incident case 127 (56) 87 (59) 0.2 (0.02, 1.4)
HIV RNA* <400 copies/ml 78 (35) 68 (46) 0.8 (0.5, 1.5) 0.03 1.7 (1.0, 2.6) 0.04
≥400 copies/ml 147 (65) 80 (54) -ref-
HAART No 54 (24) 27 (18) -ref- 0.20
Yes 171 (76) 121 (82) 1.1 (0.7, 1.7)
CD4 cells/ìl* Mean±SD 450±250 519±281 0.02 1.1 (1.0, 1.2) 0.04
CD8 cells/ìl Mean±SD 878±429 860±352 1.6 (1.0, 2.4) 0.67
Baseline HAV antibodies* <20 mIU 78 (35) 84 (57) -ref- <0.001 2.9 (1.9,4.6) <0.001
≥20 mIU 147 (65) 64 (43) 0.7 (0.4, 1.2) -ref-
#

Antibody response was defined by a ≥2-fold increase between baseline and peak antibody concentrations or by conversion from <20 to ≥20 mIU/ml.

&

Odds ratio (95% confidence interval)

$

Number (%)

*

Indicates factors that were significantly associated with antibody response to HAV vaccine in the univariate analysis.

Bold-facing underscores factors that remained significant in the multivariate analysis, which considered all significant factors identified by the univariate screen (see statistical methods) in model selection and HC use.